375 related articles for article (PubMed ID: 23665971)
21. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
[TBL] [Abstract][Full Text] [Related]
22. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
[TBL] [Abstract][Full Text] [Related]
23. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
[TBL] [Abstract][Full Text] [Related]
25. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
Yao Y; Dou C; Lu Z; Zheng X; Liu Q
Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
[TBL] [Abstract][Full Text] [Related]
26. MACC1 is related to colorectal cancer initiation and early-stage invasive growth.
Ren B; Zakharov V; Yang Q; McMahon L; Yu J; Cao W
Am J Clin Pathol; 2013 Nov; 140(5):701-7. PubMed ID: 24124150
[TBL] [Abstract][Full Text] [Related]
27. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
28. Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Omoto Y; Iwase H
Int J Oncol; 2015 May; 46(5):2143-53. PubMed ID: 25738887
[TBL] [Abstract][Full Text] [Related]
29. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of metastasis-associated in colon cancer 1 (MACC1) in HBV-related hepatocellular carcinoma].
Chang XJ; Wang CP; Qu JH; Lu YY; Chen Y; Bai WL; Gao XD; Hao LY; Xu GL; Wang H; Yang YP
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):748-52. PubMed ID: 23291068
[TBL] [Abstract][Full Text] [Related]
31. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
33. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
34. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.
Voutsina A; Tzardi M; Kalikaki A; Zafeiriou Z; Papadimitraki E; Papadakis M; Mavroudis D; Georgoulias V
Mod Pathol; 2013 Feb; 26(2):302-13. PubMed ID: 22936063
[TBL] [Abstract][Full Text] [Related]
35. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
36. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
37. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
[TBL] [Abstract][Full Text] [Related]
38. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
39. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
40. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer.
Osada S; Matsui S; Komori S; Yamada J; Sanada Y; Ihawa A; Tanaka Y; Tokuyama Y; Okumura N; Nonaka K; Hosono Y; Takahashi T; Yamaguchi K; Yoshida K
Hepatogastroenterology; 2010; 57(97):76-80. PubMed ID: 20422876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
